美国最大中毒控制系统10年单药双倍剂量摄入回顾性分析
该研究回顾性分析了加州中毒控制系统2006年1月至2015年12月报告的所有双倍剂量药物摄入病例,纳入单次单药且剂量已知的摄入共876例。根据AAPCC标准评估结局,发现抗高血压药和行为调节药各占中度及重度效应的三分之一以上。12例重度结局涉及普罗帕酮、β受体阻滞剂、钙通道阻滞剂、安非他酮和曲马多,其中血管活性药物相关者最严重,需心脏起搏和血管升压药持续输注。镇痛药、抗菌药和抗过敏药耐受良好,无死亡病例。作者认为双倍剂量摄入后重度不良结局罕见,多数可在家安全观察,但β受体阻滞剂和钙通道阻滞剂摄入需警惕血流动力学崩溃,曲马多和安非他酮需警惕癫痫发作。
要点
- 双倍剂量药物摄入后重度不良结局罕见,876例中仅12例出现重度结局,无死亡。
- 抗高血压药和行为调节药各占所有中度及重度效应的三分之一以上。
- 普罗帕酮、β受体阻滞剂、钙通道阻滞剂、安非他酮和曲马多与12例重度结局相关。
- 血管活性药物相关重度结局最严重,需心脏起搏和血管升压药持续输注。
- 镇痛药、抗菌药和抗过敏药双倍剂量摄入耐受良好,多数病例可在家安全观察。
适用人群与场景
- 2006年1月至2015年12月向加州中毒控制系统(CPCS)报告的双倍剂量药物摄入病例,纳入标准为单次单药摄入且剂量已知,涵盖所有年龄和性别。
诊断标准与关键阈值
- 采用AAPCC标准将结局分为无效应、轻度、中度、重度或死亡。
红旗征与不能漏的情况
- β受体阻滞剂和钙通道阻滞剂双倍剂量摄入需警惕血流动力学崩溃。
- 曲马多和安非他酮双倍剂量摄入需警惕癫痫发作。
- 普罗帕酮、β受体阻滞剂、钙通道阻滞剂、安非他酮和曲马多与重度结局相关,其中血管活性药物相关者最严重,需心脏起搏和血管升压药持续输注。
研究设计与关键结果
- 回顾性分析加州中毒控制系统2006年1月至2015年12月数据,1286例中876例符合纳入标准。
- 抗高血压药和行为调节药各占所有中度及重度效应的三分之一以上。
- 12例重度结局涉及普罗帕酮、β受体阻滞剂、钙通道阻滞剂、安非他酮和曲马多,其中血管活性药物相关者最严重,需心脏起搏和血管升压药持续输注。
- 镇痛药、抗菌药和抗过敏药双倍剂量摄入耐受良好,无死亡病例。
证据类型、等级与局限
- 证据类型:回顾性综述;局限:原文未报告局限性。
对床旁实践的改变
- 作者认为双倍剂量药物摄入后重度不良结局罕见,多数可在家安全观察,但存在少数例外。
- 作者认为β受体阻滞剂和钙通道阻滞剂摄入需警惕血流动力学崩溃,曲马多和安非他酮摄入需警惕癫痫发作。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Most Americans take at least one medication on a daily basis. Inadvertently ingesting a double-dose of a medication with a narrow therapeutic index may lead to adverse effects. When a patient or medical professional contacts the local poison center after an overdose, a poison specialist fields the incoming information and, depending on the caller, provides specific recommendations. We sought to determine which medication classes were most likely to lead to significant adverse outcomes when an extra dose was ingested.
METHODS: This was a retrospective review of all double-dose medication ingestions reported to the California Poison Control System (CPCS) between January 2006 and December 2015. Inclusion criteria were single-instance, single-medication ingestions where the dose was known. All ages and both sexes were included. We evaluated generalized outcomes per AAPCC criteria stratified as no effect, minor, moderate, major or death. We also documented specific symptoms and interventions noted by the poison control specialists.
RESULTS: Out of 1286 cases, 876 ingestions met the inclusion criteria. Medications with antihypertensive and behavior modulating effects each accounted for over a third of all moderate and major effects. The medications/medication classes implicated in the 12 major outcomes included propafenone, beta blockers (βBs), calcium channel blockers (CCBs), bupropion, and tramadol. Of these, vasoactive medications were associated with the most severe effects requiring cardiac pacing and vasopressor drips. Analgesics, antimicrobials, and anti-allergy medications were well tolerated. There were no deaths.
CONCLUSIONS: Major adverse outcomes after a double dose ingestion were rare. Most double dose medication ingestions can be safely monitored at home, albeit with a few exceptions. Vigilance is warranted in cases of βB and CCB ingestion due to the risk of hemodynamic collapse or seizures with tramadol and bupropion.
参考来源
- Correia MS, Whitehead E, Cantrell FL, et al. A 10-year review of single medication double-dose ingestions in the nation's largest poison control system. Clin Toxicol (Phila). 2018. PMID: 30484705. doi:10.1080/15563650.2018.1493205
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。